ENYO Pharma and the CALIPHO group at SIB Swiss Institute of Bioinformatics are pleased to announce the neXtProt data release 2020-07-17, that integrates the human protein interactome curated by the company as “GOLD” data. This dataset includes 108,000 descriptions of protein interactions from 324 papers with the capture of the experimental method (PSI-MI). When the sequence used in the protein-protein interaction experiment is known, this information has been collected and is available in neXtProt as interaction mapping annotations.
ENYO Pharma is proud to be part of the FrenchTech 120 with such promising companies. It is a strong recognition from the French State.
ENYO Pharma is pleased to announce the initiation of a bioinformatics collaboration with Lydie Lane and Amos Bairoch of the CALIPHO group, part of the SIB Swiss Institute of Bioinformatics and the University of Geneva. The CALIPHO group aims at using a combination of bioinformatics and experimental methodologies to increase the knowledge on human proteins. Together, we will integrate ENYO’s unique protein interactome datasets within neXtProt, a comprehensive human-centric discovery platform,
From Monday, September 16th, the ENYO Pharma teams will invest new premises in the BIOPARC which is being set up in LYON 8th. This is the opportunity to expand and benefit from the emulation that BIOPARC will create.
ENYO Pharma takes part to the research against Hepatitis B with the development of its FXR agonist EYP001 and support the research is this field by becoming one of the sponsor of the Hep B Foundation which is “a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide”